Researchers have identified a key enzyme driving forms of Parkinson’s, and have shown how blocking it restores normal function in animal and cell models – offering a promising new drug target for the ...

New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New ...

Novartis is returning to the alpha-synuclein protein as a possible treatment for Parkinson’s disease, signing a licensing deal worth up to $2.2bn for Arrowhead Pharmaceuticals’ preclinical candidate.

Researchers at Baylor College of Medicine have discovered a potential new strategy to fight back against Alzheimer's and Parkinson's diseases, conditions that are linked to the toxic accumulation of ...

“Taken together, our findings highlight both brain region-specific vulnerabilities and global molecular perturbations associated with alpha-synuclein biology and provide insights into early ...